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1. Introduction  
The pathology of Alzheimer Disease (AD) has been intensely studied in the last 20 years 
(Duyckaerts et al., 2009) because it is a progressive neurodegenerative disorder that causes 
dementia in approximately 10% of individuals older than 65 years (Hampel et al., 2010).  AD 
occurs gradually; starting with the so called mild cognitive impairment (MCI) recognized by 
mild memory disturbances and noticed difficulties in performing more demanding 
cognitive tasks. With disease progression the decline in memory and cognition become more 
expressed and are accompanied by changes in personality and behaviour. In later stages of 
the disease loss of speech and movement is followed by total disability and finally death. A 
person with AD lives on average eight years after the onset of symptoms (Zerovnik, 2010). 
Actual studies are focused in many strategies for markers of susceptibility, early diagnostic, 
understanding of molecular mechanism, effective treatment and preventing strategies. 
According to Duyckaerts and coworkers (2009) AD could be divided in three broad 
chapters: lesions related to abnormal accumulation of proteins, those that are due to neural 
losses and finally those that are due to the reactive processes. According to abnormal 
accumulations proteins, AD is characterized by the presence of two types of 
neuropathological hallmarks: neurofibrillary tangles (NFTs) and neuritic plaques (NP). 
NFTs are intraneuronal aggregates of abnormally modified Tau (phosphorylated at non 
physiological sites, truncation, etc). NP are extracellular and mainly composed of amyloid ǃ-
peptide (AB) deposits (Martin et al., 2011). The most of the cases of AD are reported as 
“sporadic” pathway, because we still do not know what could be the factors that lead to this 
disease. Many hypotheses has been proposed, including immune system participation 
(Solomon &Frenkel, 2010), pathogens (Miklossy, 2011), oxidative stress responses, and more. 
At the end, in patients we can always find NFTs and NP in several regions of the brain 
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(Braak &Braak, 1991). About these lesions, Braak and Braak (1991) established a relationship 
between the appearance of NP and NFTs with cognitive decline in post-mortem studies 
(Braak &Braak, 1991).  
At the moment, AD can be diagnosed conclusively only post-mortem. However, advances 
in neuroimaging by magnetic resonance imaging (MRI) and by positron electron 
tomography (PET) allow researchers to see accumulation of amyloid plaques and NFTs in 
the living brain. In such a way, the course of the disease at various time points can be 
followed and an early diagnosis obtained. One, in principle, could even monitor the 
development/progression of the disease (Zerovnik, 2010). Several evidences demonstrate 
that under the formation of these lesions, are implicated in an important manner, 
conformational changes for Tau and amyloid ǃ-peptide. Understanding the process at the 
molecular level is important for toxic aggregates could be stopped from forming or, 
alternatively, their removal could be accelerated. Antibodies directed against a common 
structural epitope shared by the prefibrillar oligomers could serve such a role. Common 
structural characteristics of amyloid fibrils are: predominantly ǃ-sheet secondary structure, 
detected by specific dyes, and binding and a characteristic pattern seen by X-ray diffraction. 
By electron microscopy amyloigenic fibrils also are visualized allowing morphological 
studies (Zerovnik, 2010). In this chapter we focus on the importance of changes in 
conformation of both proteins during abnormal aggregation associated to AD. 
2. Amyloid β  
A growing body of evidence suggests that altered processing of amyloid precursor protein 
(APP) is one of the early events in the pathogenesis of AD. APP is a transmembrane 
glycoprotein of type 1 from 120 to 200 kD wich are ubiquitously expressed, but are most 
abundant in the brain (Selkoe, 1994). The APP gene is located on the long arm of 
chromosome 21 in humans (Kang 1987) and contains 18 exons (figure 1A) through 
alternative splicing of exons 7, 8 and 15 are generated 8 isoforms that have pattern cell 
specific expression and are designated by the number of amino acids they contain. The size 
of the isoforms can vary from 563 to 770 amino acids (Coulson et al., 2000). In central 
nervous system express only 4 isoforms: PPA695, PPA714, PPA751 and PPA770, PPA695 of 
which is the most abundant isoform in neurons, while that PPA751 and PPA770 isoforms 
are expressed mainly in glial cells (Yoshikai et al., 1990; Zheng &Koo, 2006). Only isoforms 
PPA695, PPA751 and PPA770 contains the sequence encoding the amyloid-ǃ (AB) peptide 
(Golde et al., 1990; Kang et al., 1987). The full-length APP (APP 770) consists of 18 exons, 
where exon 17 resembles the membrane spanning domain. APP 695 lacking both, exon 7 
and exon 8 is primarily expressed by neurons and is the most abundant APP transcript in 
the brain (Neve 1988).  APP 751 (lacking exon 8), APP 714 (lacking exon 7) and APP 770 
were first identified in peripheral organs but are also expressed in brain glial cells. Other 
alternatively generated splice variants of APP involving exon 15 were recently discovered in 
peripheral leucocytes and in microglial cells and therefore denoted as leukocyte- derived 
APP (L-APP) (Konig et al., 1992). The AB fragment is part of exon 16  and 17 (figure 1B) and 
begins 99 amino acid  residues from the carboxy terminus and extends 12-15 residues into 
the hydrophobic  membrane domain (Estus et al., 1992). The APP protein is composed of 
three regions: a large extracellular domain in the N-terminal region that forms a globular 
structure, a transmembrane region, which contains part of the AB sequence, and a small 
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cytoplasmic domain laregion C-terminal (figure 1B). The overall structure includes the 
position of a heparin binding domain, metal binding domains, sites of phosphorylation and 
glycosylation. Two of the isoforms (APP 751 and APP 770) have a domain Kunitz-type 
protease inhibior (KPI) and a signal peptide (De Strooper, 2010). 
 
Fig. 1. Characteristics of APP and processing (A) Exon structure of human APP gene 23. 
Exons are indicated by rectangles. Alternatively spliced exons are 7, 8 and 15. Functional 
protein domains are indicated by different colors. Distances between exons are not 
representative. (B) Schematic representation of human APP protein including the relative 
position of the ǂ-, ǃ- and Ǆ-secretase cleavage sites. KPI: Kunitz-type protease inhibitor 
domain, AICD: APP intracellular domain, YENPTY: motif that binds he phosphotyrosine 
binding (PTB) domain of X11. (C) Schematic diagram of APP processing pathways. APP 
proteolytic catabolism includes two different pathways: an amyloidogenic pathway and a 
non-amyloidogenic pathway (constitutive secretary pathway). The different APP fragments 
are generated after secretase cleavage.  
In brain tissue, APP can be processed in two ways: non-amyloidogenic and amyloidogenic 
pathway. In the non-amyloidogenic pathway, APP is first cleaved by ǂ-secretase within the 
AB sequence, which releases the sAPPǂ ectodomain. Further processing of the resulting 
carboxyl terminal by Ǆ-secretase results in the release of the p3 fragment and AICD (figure 
1C) (Greenwald &Riek, 2010). The most prevalent area of research in AD studies the 
proteolytic generation of AB from APP. The ǃ-secretase and Ǆ-secretase cleave APP in the 
so-called amyloidogenic pathway ǃ-secretase release the ectodomain sAPPǃ, and the 
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remaining APP carboxy-terminal fragment (C99) is subsequently cleaved by the Ǆ-secretase 
liberating the secreted AB peptide(s) and the APP intracellular domain (AICD) (figure 1C). 
The biological functions of sAPPǃ, AB, and the AICD remain rather elusive, although AB 
release is associated with synaptic activity, depression excitatory synaptic transmission onto 
neurons. The production of AB occurs naturally inside the human brain, these fragment 
possesses and amphiphilic structure with hydrophilic N- and hydrophobic C- terminus, 
however the C-terminal end is variable ranging at least from 37 to 42 residues; the most 
studied forms are AB 1-40 and AB 1-42 that consist of 40 and 42 residues respectively 
(Fandrich et al., 2011). Under physiological conditions, the ratio of AB42 to AB40 is about 
1:10. AB42 plays a critical role in the pathogenesis of AD since its aggregative ability and 
neurotoxicity are much greater than those of AB40 (De Strooper, 2010). 
About APP function, the analysis sequence and structure indicate that the protein is 
organized into different domains, because it is believed that APP is important for functions 
as neuronal survival, synaptogenesis, cell adhesion, inhibition of clotting factors, inhibiting 
platelet activation and in the modulation of copper homeostasis (Chow et al., 2010; De 
Strooper, 2010). The precise function of various APP isoforms in the brain is still unknown. 
It has been suggested that APP plays a role in establishing or maintaining cell-cell contacts 
which is also consistent with preferential localization of APP at nerve terminals, because 
have been shown their interaction with extracellular matrix proteins and heparin sulfate 
proteoglycans through E1 and E2 regions of APP (Schubert et al., 1995; Small et al., 1999). 
The function of APP as a cell surface receptor has been proposed for the evidence of AB 
could bind to APP and also the similarities of their secondary structure with Notch receptor 
(Zheng &Koo, 2011). About the neuronal survival and synaptogenesis functions of APP the 
reports showed that APP expression is upregulated during neuronal maturation and 
differentiation, also induced after traumatic brain injury, these results are reinforced because 
the reduction of APP is associated with neuronal impairment (Hung et al., 1992; Leyssen et 
al., 2005). The APP can be phosphorylated at multiple sites resulted in several consequence 
such as localization to the growth cones and neuritis (Muresan &Muresan, 2005). Other 
contrasting activity of soluble APP is the cytotoxic properties of C99 fragment as result of ǃ-
secretase cleaveage (Neve et al., 1996). Meanwhile, the functional properties of AB peptides 
have not been fully clarified to date, although numerous studies suggest that peptides have 
a number of neurotrophic and neurotoxic properties (Tycko, 2011). It is suggested that AB 
soluble plays an important role in neuronal growth, survival, and synaptic modulation, 
while the oligomers and fibrils have toxic properties (Kamenetz et al., 2003; Plant et al., 2003; 
Puzzo et al., 2008). Studies have shown that AB oligomers are able to induce increased cell 
death and apoptosis soluble or fibrillar forms, suggesting that the structural conformation 
peptide is important in determining its physiological action (Small et al., 2001). 
2.1 Amyloid β structure and aggregation  
Recent biophysical investigations using electron microscopy, Fourier Transform Infrared 
Resonance (FTIR) studies and Circular Dicroism (CD) spectroscopy showed that AB fibrils 
adopt a ǃ-sheet structure (Serpell et al., 2000). However, a high-resolution structural analysis 
of AB fibrils has yet to be conducted since single crystal X-ray crystallography and solution 
nuclear magnetic resonance (NMR) cannot be applied to insoluble AB fibrils (Greenwald 
&Riek, 2010). AB peptides generated can exist as monomers, dimers and oligomers with 
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aggregation and eventually produce protofibrils fibrils, they acquire a conformation which 
ǃ-pleated sheet. The AB peptide has a spontaneous tendency to oligomerization, forming 
toxic species which can even add intracellularly and therefore believed to play a role this 
fundamental neurotoxicity in AD (Klein et al., 2001; Murray et al., 2009). Recent experiments 
have established that the main structure adopted by these peptides depends on the 
environment. The monomers contain a amphipathic sequence that favors the ǂ-helix 
structure in solution but preferred aqueous ǃ-pleated structure (Greenwald &Riek, 2010). 
The structures of ǃ-sheets are parallel or anti-parallel alignments of two or more ǃ-stranded 
peptides that are held together by inter-strand hydrogen bonds. The ǃ-sheet is not an 
unusual structure with more than 30% of the secondary structure of all proteins. The 
structure consisting of strands aligned in parallel feature twelve-membered hydrogen 
bonded rings, while those with strands in anti-parallel arrays are characterized by 
alternating 10- and 14-membered H-bonded rings. Dihedral angles commonly found in 
parallel (φ = –119°, ψ = 113°) and anti-parallel (φ = –139°, ψ = 135°) ǃ-sheets are closer to 
those of the fully extended single-strand conformation (φ = ψ = ±180°) than ǃ-turns or ǂ-
helices. The ǃ-sheet usually acts as a scaffold to stabilize protein architecture, but it is also an 
important recognition motif in some protein–protein and protein–DNA interactions that 
mediate biological processes and some notable diseases (Harrison et al., 2007; Jenkins 
&Pickersgill, 2001). The peptide self-assembly to AB fibrils is a widespread phenomenon in 
nature; these structures are associated with protein aggregation pathologies such as AD. 
Therefore the structural analysis of AB fibrils is one of the most promising ways of revealing 
the mechanism involved in this event. Investigations showed a conserved evolutionarily 
protein motifs. The description of a common cross-ǃ structure consists of ǃ-strand peptides 
aligned in either parallel or antiparallel orientations to provide ǃ-sheet structures that 
ultimately laminate to form fibrillar architectures. This process is mediated by noncovalent 
forces such as hydrophobic and hydrogen bonding interactions. However, the contribution 
of these forces is poorly understood (Bemporad et al., 2006; Tycko, 2011). Other critical 
interactions in cross-ǃ peptide self-assembly are aromatic π-π, frequent in aromatic amino 
acids in the core of amyloid sequences, because mutations o deletions cause the loss of the 
structure (Bowerman et al., 2011; Marshall et al., 2011). Fibrils of AB42 and AB10-35 show a 
strong dependence of pH on morphology observed; at pH 7.4 protofilaments of AB42 exist 
singly and in pairs, but protofilaments of AB10-35 exist in pairs only. Studies on NMR 
indicate a parallel ǃ-sheet organization on AB42 fibrils, consistent with supramolecular 
structures of other fibrils of AB10-35 and AB40. Although, there is a disagreement in the 
results obtained for fibrils formed by AB10-35 and AB40 with parallel organization, while 
the observations in AB42 fibril showed an antiparallel ǃ-sheet structure. The explanation is 
that amyloid fibrils do not have a universal supramolecular organization. Also the results 
obtained of electronic microscopy and diffraction support a tubular structure for AB fibrils 
(Antzutkin et al., 2002). Analysis of the amyloidogenic regions in fibril-forming proteins 
showed a high occurrence of the aromatic residues phenylalanine and tyrosine, which have 
a high propensity to stack the delocalized π-electron rings in a parallel manner. Studies with 
short peptides have confirmed that even two consecutive phenylalanine residues are 
sufficient to facilitate assembly into nanotube-like structures, and stacks of aromatic 
residues were observed in crystal structures (Nerelius et al., 2010). 
Also it has been suggested that the amphiphilicity of the peptide plays a significant role in 
determining whether peptide strands within the fibril are parallel or anti-parallel. Parallel ǃ-
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sheets in proteins usually adjoin ǂ-helices, suggesting that they are intrinsically less stable 
on their own than are anti-parallel ǃ-sheets. The AB40 and AB10–35 peptides both have 
hydrophobic C-termini, and their reported assembly into parallel ǃ-sheets allows the 
juxtaposition of the hydrophobic portions of the peptides, shielding them from aqueous 
solution. An anti-parallel disposition would be costly energetically because of the forced 
association of hydrophobic and hydrophilic regions. AB16–22 and AB34–42 both have a 
centrally located hydrophobic segment and thus no advantage of sequestration of 
hydrophobic regions provided by either a parallel or antiparallel arrangement. The anti-
parallel ǃ-sheet arrangements found for these two peptides may then be the result of 
favorable charge interactions between side chains or termini, or improved H-bonding 
(Harrison et al., 2007). A model proposed for this structure is a parallel ǃ-helix consisting of 
an extended polypeptide chain wrapping around a cylindrical template, where adjacent 
strands of the helix are connected through H-bonds and is based on two key features of the 
polyglutamine diffraction data; the absence of a 10-Å reflection and the presence of a weak, 
low-angle reflection of 31 Å (Perutz et al., 2002). 
The crucial region for the formation of crossed-ǃ fibrils is found in 15-23 residues 
(QKLVFFAED) (figure 2A), substitution of Thr for Phe19 can abolish plaque-forming 
competence of the mutant peptide and that the mutant peptide was significantly less folded 
in aqueous buffer than the wild-type peptide. Further, the Phe19 in the AB antiparallel ǃ-
sheet is key in determining the properties of the fibril, because the observation that the Thr 
for Phe19 substitution lacks fibril-forming competence. Also the Lys16 in AB is positioned 
for electrostatic interaction with the charged sulfate groups of inductors of aggregation such 
as Congo Red (Carter &Chou, 1998). The KLVFFAED motif, a known amyloidogenic 
sequence of the AB, which contains positively and negatively charged residues (figure 2B) 
and has a high ǃ-strand propensity (figure 2C). As mentioned above, minor alterations in 
sequence, such as replacement of Val or Phe with Leu or Ala, can abolish fibril formation 
and that the amyloidogenic properties of short peptides can be abolished by introduction of 
adjacent sequence motifs such as ǃ-turns. These data indicate that both the amino acid 
sequence as such and its structural context affect the ability to form amyloid fibrils (Nerelius 
et al., 2010). In macromolecular level, aggregates are typically fibrillar in electron 
microscopy images generally with linear (figure 2D), unbranched fibrils of variable length. 
Each fibril is thought to consist of several protofilaments, the number being specific to the 
particular amyloid protein. Improved imaging of protofilaments has revealed that certain 
fibrils are clearly helical, with the protofilaments slowly twisting around each other. For 
Aǃ34–42 fibrils, the twisted fibril “unwinds” under denaturing conditions and for Aǃ40 at 
high pH, suggesting that these protofilaments are associated through both electrostatic and 
hydrophobic interactions (Fraser et al., 1992; Halverson et al., 1990). Amyloids are typically 
large (Megadalton) elongated structures with varying lengths and often varying 
ultrastructural appearances (Toyama &Weissman, 2011). Here we describe some of the most 
commonly used techniques employed in amyloid structure characterization. Electron 
microscopy and atomic force microscopy (AFM) are the two most widely used microscopy 
techniques employed in the study of amyloids. Both provide a nanometer-resolution 
perspective of the ultrastructural characteristics of amyloids. This includes amyloid fiber 
length and width, morphology such as curvature and persistence length, surface 
characteristics such as periodic twists, and higher-order assembly. Electron microscopy and 
AFM helped establish many of the common ultrastructural characteristics of amyloid fibers, 
such as the long, relatively straight and unbranched nature of the fibers; the typical fiber 
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width of 5–15 nm; the periodic twist often observed; and the conclusion that many amyloid 
fibers are made up of the bundling of thinner protofibrils. To better understand the higher-
order assembly of amyloid fibers, scanning transmission electron microscopy (STEM) and 
tilted-beam transmission electron microscopy, both forms of electron microscopy, have 
provided data that describe the amount of mass-per-unit length (MPL) of amyloids. These 
data are particularly valuable in determining how many monomers make up a single layer 
of the fiber structure. AFM has also been used to determine the relative fiber rigidity by 
monitoring its propensity to bend. Electron microscopy and AFM both have the advantage 
of being single-fiber approaches, which are useful in visualizing structural heterogeneity 
within a single-fiber preparation (Chen et al., 2009; Shirahama &Cohen, 1965). 
 
Fig. 2. Characteristics of Amyloid ǃ. (A) Structure diagram and amino acid sequence of 
AB42. (B) Amino acid distribution histogram of AB42. (C) Proposed AB42 structure based 
on predicted ǃ-strand propensities (Displayed in Jmol). (D) Electron Microscopy 
photograph of in vitro AB42 aggregates.  
Fiber X-ray diffraction was one of the first structural techniques that provided a substantial 
clue to the overall fold of amyloid fibers. In this method, fibrous samples are bombarded 
with X-ray radiation, and diffraction patterns result from interference patterns from any 
regularly spaced structural features present in the fibers. As alluded to above, this technique 
established the cross-ǃ diffraction pattern interpreted as ǃ-sheets parallel to the fiber axis, 
with ǃ-strands perpendicular. It has also aided in testing the validity of particular model 
structures. Here, a theoretical Xray fiber diffraction pattern is calculated on the basis of a 
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particular model and then is compared to an actual diffraction pattern (Makin et al., 2005). 
FTIR and CD are absorptive spectroscopic techniques that measure nonsymmetrical or 
chiral molecular systems in bulk, FTIR spectroscopy measuring molecular bond vibrational 
frequencies and CD the differential absorption of left versus right circular polarized light. 
Both of these properties are highly sensitive to secondary structure, and therefore, 
deconvoluted FTIR and CD spectrum provide accurate estimations of the contribution of ǃ-
sheets, ǂ-helices, and loops to the overall structure (Berthomieu &Hienerwadel, 2009; 
Ranjbar &Gill, 2009). Cryoelectron Microscopy: is a technique that positions itself as a capable 
alternative to conventional X-ray crystallography and solution NMR in amyloid structure 
determination. Unlike X-ray crystallography, proteins of interest need not be in a crystalline 
form for cryoelectron microscopy; rather, structural data can be acquired on single particles. 
Furthermore, amyloid preparations do not need to be labeled with stable isotopes, is the case 
with NMR, nor do they even need to be highly pure preparations. This is particularly 
advantageous owing to the inherent heterogeneous nature of the amyloid conformation 
(Mizuno et al., 2011). X-Ray Crystallography: although the large and heterogeneous nature of 
amyloid fibers would seem to be incompatible with X-ray crystallography, Eisenberg and 
colleagues have been able to acquire adequate diffraction data from microcrystals of short 
peptides (6–7 residues) that formed amyloid-like structures. Based on X-ray crystallography 
showed that structures bore strong resemblance to many existing models of amyloid fibers, 
suggesting they may in fact represent the structure of the amyloid fold. Since this initial study, 
multiple amyloidogenic peptides have been successfully crystallized and their structures 
solved (Nelson et al., 2005; Wiltzius et al., 2009).  
AB early aggregates also can showed a globular appearance that further organize into 
beaded chains, globular annular “doughnut” shaped assemblies eventually giving mature 
protofilaments and fibrils. Pre-fibrilar aggregates may interact with reconstituted 
phospholipid membranes and with cell membranes where they form aspecific channels 
(pores) disrupting cellular homeostasis (figure 5). The latter possible mechanism of toxicity 
is similar to that displayed by antimicrobial peptides, pore-forming eukaryotic proteins and 
bacterial toxins and newly synthesised cyclic peptide antibiotics (Stefani &Dobson, 2003).  
The cell membrane could be a nucleating center for amyloid aggregation. The evidence 
showed that AB species are tight binding to GM1 ganglioside (GM1), in the brain showing 
early pathological changes of AD. The ganglioside-bound AB (GAB) possessed unique 
characteristics, including its altered immunoreactivity, which suggests its distinct 
conformation from native AB, and its strong potency to accelerate Aǃ assembly into fibrils. 
The hypothesis is that AB adopts an altered conformation following interaction with GM1, 
leading to the generation of GAB, and then GAǃ acts as an endogenous seed for Alzheimer 
amyloid in the brain. GAB is favorably generated in the unique ganglioside-enriched 
(clustered), raft-like microdomains; moreover, amyloid fibrils formed in the presence of 
gangliosides are neurotoxic. Probably the ganglioside binding is the initial and common 
step in the development of a part of human misfolding-type amyloidoses, including AD 
(Matsuzaki et al., 2010). Recent reports supports that soluble oligomers of AB may be the 
key neurotoxic species associated with the progression of AD and that the process of AB 
aggregation may drive this event. Recent data obtained in our laboratory suggest that the 
presence of soluble oligomers in rat hippocampus promotes localized mechanism of 
inflammatory responses (unpublished data). Is alspo reported that soluble oligomers of AB 
and Tau accumulate in the lipid rafts of brains from AD patients through an as yet unknown 
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mechanism. In cell culture models the exogenously applied AB in the form of oligomers can 
be trafficked on the neuronal membrane and accumulate in lipid rafts. The oligomers 
induced dynamic alterations in lipid raft protein composition were found to facilitate this 
movement. There is a clear association between AB accumulation and redistribution on the 
neuronal membrane and alterations in the protein composition of lipid rafts. Also the 
reports showed that fyn is a key protein on AB redistribution and accumulation in lipid rafts 
as and mediating the cell death induced by the AB oligomers and defines a mechanism by 
which oligomers of AB and Tau accumulate in lipid rafts (Williamson et al., 2008). 
3. Tau protein 
Tau is a microtubule-associated protein (MAP) that is believed to stabilise microtubules and 
to promote microtubule assembly. Of the neuronal MAPs, it is one of the most abundant 
(Goedert &Spillantini, 2011). Tau protein is found in many animal species such as 
Caenorhabditis elegans, Drosophila, goldfish, bullfrog, rodents, bovines, goat, monkeys and 
humans (Buee et al., 2000). In humans, Tau is encoded by a single-copy gene located on 
chromosome 17q21.1 in humans (figure 3A). It produces three transcripts of 2, 6 and 9 kb 
which are differentially expressed in the nervous system, depending upon stage of neuronal 
maturation and neuron type. The 2 and 6 kb Tau mRNAs arise from utilization of two 
alternative polyadenylation sites separated by ~4 Kbp. So far, one promoter has been 
mapped for the Tau gene in both human and rat, located directly upstream of Tau exon -1. 
However, the 6 kb Tau transcript is responsive to NGF, whereas the 9 kb one is not. Also, 
the 6 and 9 kb transcripts are restricted to neuronal tissues, whereas the 2 kb Tau transcript 
is ubiquitous (Andreadis, 2005; Andreadis et al., 1996). Tau primary transcript contains 16 
exons, but two of them (exons 4A and 8) are not present in mRNA in human brain. Exon 4A 
is present in peripheral nervous system not only in humans, also in bovine and rodent 
peripherial tissues. On the other hand, exon 8 has not been described in humans. Exon -1 is 
part of the promoter, transcribed but not translated, just like exon 14 (Buee et al., 2000). Exon 
3 is never found without exon 2, and as exon 10, are present in an adult-specific manner 
(figure 1B), but their ratios differ in various central nervous system compartments 
(Andreadis, 2011; Takuma et al., 2003). All six possible product combinations of the 2/3/10 
splicing events have been observed (figure 3B), indicating that separate factors govern their 
splicing (Andreadis, 2011). Alternative splicing of hinge-region exon 6 gives rise to Tau 
variants that lack the domain responsible of microtubule binding, and is mentioned that 
alters Tau function (Andreadis, 2011; Luo et al., 2004).  Saitohin (STH), an intronless gene 
encoding an open reading frame of 128 amino acids, is located in the intron between exons 9 
and 10 of the human Tau gene (Wang et al., 2011). Recently has been associated the existence 
of a polymorphic form with AD, but is still under research. In the 6 principal human Tau 
protein isoforms are present two domains (Figure 2C): the projection domain located in the 
amino-terminal and is composed of an acidic region and a proline rich region (PRR). The 
other domain is named microtubule binding domain (MTBD), which contain  the C-termini 
per se, and a microtubule binding region (MTBR), conformed indeed by the presence from 
three (3R) to four repeats (4R) (Buee et al., 2000). They differ from each other by the presence 
or absence of 29- or 58-amino acid inserts located in the amino-terminal half and an 
additional 31-amino acid repeat in the carboxy-terminal half (Goedert &Spillantini, 2011). 
Tau is enriched in axons of growing and mature neurons and is critical for neuronal 
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function. Among its many roles, Tau promotes neurite outgrowth, organizes axonal 
microtubules (MTs) and is involved in kinesin-dependent axonal transport (Andreadis, 
2011; Hirokawa et al., 1988; LaPointe et al., 2009). Additionally, the interaction of Tau with 
diverse structural and functional proteins suggests that Tau may play crucial roles not only 
in normal architecture but also in signal transduction of the neurons (Wang &Liu, 2008). The 
acidic sequences may be involved in cation binding and in iron binding site motif, also is  
 
Fig. 3. Characteristics of human Tau protein. (A) Human Tau gene presents 14 exons and -1 
is part of the Tau gen promotor: -1 and 14 can be transcribed but not translated; in human 
CNS are not normally expressed exons 4A, 6 and 8. In all isoforms are expressed exons 1, 4, 
5, 7, 9, 11, 12 and 13. Exons 2, 3 and 10 can be excluded depending of Tau isoform. In exon 9 
is codified the protein Saitohin. Exons are indicated by rectangles. Distances between exons 
are representative. (B) Tau isoforms expressed in human CNS, showing number of 
aminoacids and inserts that differ each of them. Functional protein domains are indicated by 
different colors (C) Domains contained in most of the isoforms of human Tau protein: the N-
terminal is named projection domain and is subdivided in acidic domain and proline rich 
regions; also here is a PXXP motif for SH3 domain interactions. The C-terminal, also named 
microtubule binding domain (MTBD) contains the MTBR and the C-terminus per se; in 4R 
isoforms is present 2 sequences with ǃ sheet structure tendency adjacent to the second and 
third repeats. P= phosphorylation sites; = truncations sites. 
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proposed that the motif KKXK is involved in heparing binding (Ávila et al., 2002) and actin 
interaction (Zmuda &Rivas, 2000). In this regions is present various PPXXP or PXXP motifs 
which allow Tau protein to interacts with SH3 domains of diverse proteins such as Src 
family members like Fyn, Lck, Src (Lee, 2005; Lee et al., 1998; Scales et al., 2011) and others 
like PCL-Ǆ (Hwang et al., 1996; Jenkins &Johnson, 1998). Is also mentioned that STH 
interacts with Tau and Abl and influences in Abl phosphorylation (Wang et al., 2011), but 
this phenomena needs further research. 
The efficacy of Tau to binding MTs is influenced by the degree of phosphorylation and the 
exclusion/inclusion of exon 10. The affinity of Tau against MTs is weaker in 3R isoforms 
than 4R isoforms, perhaps leading to differential regulation of microtubule behaviour 
(Eckermann et al., 2007; Goode et al., 2000; Lu &Kosik, 2001). Another important factor 
influences Tau-MTs interaction: site-specific phosphorylation. This is due to the high 
frequency of phosphorylatable residues (45 S, 35 T and 5 Y in the largest isoform), combined 
with the open structure of Tau which renders it accessible to many kinases (Mandelkow et 
al., 2007). The majority of the phosphorylation sites are Serine or Threonine residues 
followed by Prolines (SP/TP motifs) that lie in the domains flanking the repeats and can be 
phosphorylated by several Proline-directed kinases and by neuronal kinases MARK 
(affecting the KXGS motifs within Tau's repeat domain) (Eckermann et al., 2007; Trinczek et 
al., 1995). Among the kinases responsible for Tau phosphorylation are Glycogen Synthase 
Kinase 3ǃ (Lin et al., 2007), cyclin-dependent kinase 5 (Cdk5), MT-affinity regulatory kinase, 
cAMP-dependent protein kinase (Johnson &Stoothoff, 2004), dual-specificity tyrosine-
phosphorylated and regulated kinase 1A, Tau–tubulin kinase 1, and calmodulin-dependent 
protein kinase 2 (Meraz-Ríos et al., 2010) 
3.1 Tau conformational changes in physiological and pathological conditions 
Tau is a highly flexible and extended protein, natively unfolded and with hydrophilic and 
basic character, highly soluble shown by sequence analysis and CD experiments 
(Eckermann et al., 2007; Shkumatov et al., 2011). Firstly was suggested that Tau in solution 
may be as much as 77% random coil and behave like “Gaussian coils” or “worm like-
chains”, in which the direction of the polypeptide backbone chain varies in a more-or-less 
random fashion (Goode et al., 2000). However, a potential ǃ-pleated region has been 
proposed for the microtubule binding region (Ávila et al., 2002). When Tau is attached to 
MTs, is suggested to assume an “L” conformation, meaning that MTBR interacts with the 
MTs and the N-termini is projected to cytosol, where can interacts with other proteins 
(Hirokawa et al., 1988; Mandelkow et al., 2007; Sillen et al., 2007). 
On the other hand, is suggested by fluorescence resonance energy transfer (FRET), electron 
paramagnetic resonance (EPR) and small-angle X-ray scattering that Tau can adopt a global 
hairpin (paperclip) structure in solution (when is not attached to MTs) (Jeganathan et al., 
2008a; Mandelkow et al., 2007; Mylonas et al., 2008). From a structural perspective, the 
folding of the N- and C-domains over the repeat domain would be expected to protect 
against aggregation, and indeed Tau forms aggregates more readily when the non-repeat 
domains are cleaved off (Mylonas et al., 2008). The conversion of certain soluble peptides 
and proteins into insoluble filaments or misfolded amyloid proteins is believed to be the 
central event in the etiology of a majority of neurodegenerative diseases (Nonaka et al., 
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2010). Tau protein is not the exception. Despite its random coil appearance in solution, Tau 
assembles into well-defined fibbers, the Paired Helical Filaments (PHFs) (von Bergen et al., 
2000). The appearance of conformational changes in Tau as early alterations in AD 
neuropathology has been eloquently confirmed in several studies (Ávila et al., 2002). Even 
when is reported that ǂ-helix structures are present in PHFs (Sadqi et al., 2002), the ǃ-sheet 
structure seems to be the major structure involved in Tau aggregation. Two hexapeptides, 
275VQJINK280 and 306VQJVYK311 which are respectively located at the beginning of the 
second and third MTBR are prominent in generating ǃ-sheet structures during Tau 
aggregation process (Martin et al., 2011). These hexapeptides structure are well 
characterized by several methodologies, like FTIR,  AFM and CD (Chaudhary et al., 2009). 
Another reports mention that proline is frequently involved in a ǃ-turn by reason of its 
restricted ø angle and that the Pro-Gly motif is favored to make a Type II ǃ-turn and the 
SPXX motif is known to stabilize ǃ-turns, independent of X. Also is predicted that Tau 
contains 54 ǃ-turns involving about 35% the protein sequence (Goux, 2002). For the 
conformational studies, Goux (2002) mentions that is important to consider factors as 
temperature or solvent-induced changes in Tau to the cis-trans proline distribution of 
isomers, resulting in a change in protein conformation, also mentioned by other authors for 
the two hexapeptides mentioned before (Chaudhary et al., 2009; Goux, 2002).  
As a general view for aggregation studies, conformational changes have been studied by the 
use of aggregations inducers or punctual mutations in the MTBR. The other manner is by 
promoting post-translational modifications in Tau molecule, such as phosphorylations or 
truncations or by the analysis of PHFs. In the presence of pro-aggregatory factors as 
polyanions, stimuli the assembly of full lenght Tau, 3R or 4R, and when mutations forms 
associated to other Tauopathies seem to be a faster process of filament formation. In both are 
reported the presence of ǃ-sheet enriched structures (Friedhoff et al., 2000). The ǃ-strands 
usually run perpendicular to the helix axis forming a cross-ǃ motif. By in vitro assays, is 
suggested that ǃ-sheet structures might be stabilized by the presence of salt bridges or by 
hydrogen bonds, which promote forming a continuous ǃ-sheet extending along the axis 
(Berriman et al., 2003; Jeganathan et al., 2008b). Such structures can be stained with certain 
dyes such as Congo red (CR), Thioflavine S (TS) or Thiazine Red (TR) which are thought to 
interact with the repeating ǃ strands (Glenner et al., 1972; Luna-Muñoz et al., 2008; Zilka et 
al., 2006). Planar aromatic dyes as CR, TR, and TS also are capable of inducing Tau 
fibrillization in vitro. In our group we developed a cellular model to study the particularities 
of these dyes at in vivo Tau aggregation. The SH-SY5Y cells were incubated with each dye 
and our results showed that three dyes gave rise to aggregates of Tau with different 
morphological characteristics. This method can be used to test related drugs with inhibitory 
potential for Tau abnormal polymerization (Lira-De León et al, unpublished data).  
Alternatively, Tau can indeed adopt distinct conformations has been observed in sequential 
phosphorylation reactions. This theory is supported by biophysical evidence showing that 
Tau paracrystals become longer and stiffer following phosphorylation, suggesting a 
conformational change of the protein upon phosphorylation; specifically NMR and CD 
evidence shows that a Tau peptide undergoes a conformational change following 
phosphorylation at Thr231 and Ser235 (Goux, 2002). Moreover, where the AD-specific 
phosphoepitope of antibody AT-100 in the proline-rich region can only be generated by a 
sequential phosphorylation of Tau first by GSK-3ǃ (at Thr212) and then by PKA (at Ser214), 
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indicating that pre-phosphorylation at certain sites can alter the conformation such that 
other phosphorylation reactions are no longer possible (Friedhoff et al., 2000). Tau abnormal 
phosphorylation at specific sites are strongly associated to other post-translational 
modifications such endogenous proteolysis or truncation. This abnormal process is defined 
as a protein cutting that could also promote aberrant aggregation (Ávila et al., 2004) In the 
case of Tau molecule, the lost of any of its C- and N-extremes leads to a change of properties 
of the molecule. The lost of the N-terminal has been proposed as an early event in Tau 
aggregation process because of the capability of this extreme of inhibit Tau oligomerization 
in vitro (Ghoshal et al., 2002; Horowitz et al., 2006) On the other hand, C-terminal proteolysis 
is strongly correlated with neuropathological lesions and cognitive impairment (García-
Sierra et al., 2001; Meraz-Ríos et al., 2010). Latest years many reports have demonstrated the 
relationship between site-specific phosphorylation at sites Ser199, Ser202, Thr205, Thr212, 
Ser214, located in proline-rich region, and Ser396 and Ser 404, located near C-termini. These 
impact in conformation of Tau, and perhaps expose sites for further specific proteolysis in 
Asp421 and Glu391 (Fischer et al., 2009; Jeganathan et al., 2008a; Luna-Muñoz et al., 2007; 
Mondragon-Rodriguez et al., 2008). Specific Tau-phosphorylation also alters microtubule- 
binding capacity and increase rate of filament nucleation (Chang et al., 2011; Fischer et al., 
2009). With this issue, is proposed the sequential relationship between phosphorylation→ 
conformational change→ truncation, which can be repeated until Tau protein lost their N- 
and C-termini, exposing a minimal resistance protease region named PHF-core (figure 3) 
(Binder et al., 2005; García-Sierra et al., 2008; Wischik et al., 1985; Wischik et al., 1996). The 
dense core of PHFs is compound of the repeat region of the Tau protein, forming a fuzzy 
coat beside the filament with N- and C-termini of the protein(Skrabana et al., 2004). 
According to in vitro assays, this PHF-core is able to promote Tau aggregation (Campos-
Peña et al., 2009; Wischik et al., 1996). 
Considering these data, is important to use diverse strategies for the study of this 
phenomena. For elucidated this issue is used conformational-specific antibodies. The Alz-50 
and MC-1, two conformational sensitive antibodies, have been demonstrated to recognize a 
pathological conformation of Tau molecule in NFTs (Jicha et al., 1997; Lin et al., 2007). Either 
antibody recognizes the N-termini nearby C-termini, determinate by fluorescence lifetime 
imaging and other techniques (Hyman et al., 2005). Even these antibodies recognize a region 
in the N-termini (7-9) and C-termini (312-342), both conserved in all Tau human isoforms, in 
tissue they have a distinct pattern of signal (Jicha et al., 1997). In AD brain, MC1 stains 
“pretangle neurons”, and its immunopositivity is indicative of very early neuronal 
pathological changes. Alz50 stains both pretangle neurons, as well as early-formed paired-
helical filaments (Nogalska et al., 2011). Moreover, a number of studies have proposed that 
the phosphorylation modification at S-P or T-P motifs in Tau might cause Tau 
conformational change and the cis-trans isomerisation, made by the prolyl-peptide isomerise 
Pin-1, might regulate Tau function. This association is dependent on a folding of the Tau 
molecule, this bend occurring locally in the vicinity of Thr231-P motif, and actually 
recognized by TG3 antibody (Friedhoff et al., 2000; Lin et al., 2007; Luna-Muñoz et al., 2005; 
Weaver et al., 2000). The antibody Tau-66 is another conformational-associated antibody, 
recognizing residues between 155-244 and 305-314. This antibody recognizes NFT, and also 
cytoplasmic points on some non-fibrillary neurons, mostly associated to truncated N- and C-
termini (García-Sierra et al., 2003). During this study, they suggest there is a progression 
from Alz-50 to Tau-66 conformation during NFTs evolution. Related to this, Goux based on 
PHFs extraction and CD assays, mention that Tau has a structure containing 31-37% helix, 
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15-20% ǃ-sheet, 20-23% turn, and 26-29% unordered structure (Goux, 2002), perhaps 
influencing in this “specific-antibody” conformation. It was also mentioned by Barghorn 
and co-workers that for aggregation issues, Tau must adopt a specific conformation that 
allows a subsequent fibril formation (Barghorn &Mandelkow, 2002). Recent studies use 
mAb423 antibody, which recognize truncated Tau in Glu391, as a tool for structural studies 
directed to the PHF core (from 297-391 of 441 isoform), allowing to estimate the enrichment 
of ǃ-sheet structures (Sevcik et al., 2007; Skrabana et al., 2010; Wischik et al., 1985). In this 
aim, antibodies have probe been an important tool for recognize conformational changes in 
Tau during aggregation events. 
3.2 Impact of Tau conformational change during aggregation process 
Partially folded or misfolded states often tend to aggregate because these forms typically 
expose hydrophobic amino acid residues and regions of unstructured polypeptide 
backbone, features that are largely buried in the native state. Like intramolecular folding, 
aggregation, i.e., the association of two or more non-native protein molecules, is driven by 
hydrophobic forces and predominantly results in the formation of amorphous structures 
that lack long range order. Although the toxic principle operating in the age-of-onset 
diseases is far from being understood, a consensus is emerging that oligomeric, soluble 
states of the respective disease protein are the primary cytotoxic species (Vabulas et al., 
2010). Tau proteins fibrillize efficiently in vitro into ǃ-pleated sheet structures with 
biochemical and biophysical properties of amyloid fibrils (figure 4A-B), but they do so only 
in the presence of negatively charged cofactors such as heparin, RNA, or DNA. The kinetic 
profile of Tau fibrillization in vitro generally resembles that of other amyloid proteins,  when 
is important an increase of ǃ-sheet structures (figure 4C), with a lag phase during which 
time nucleating units are believed to be formed followed by rapid fibril growth (Congdon et 
al., 2008; Matthes et al., 2011; von Bergen et al., 2000; Xu et al., 2010). Covalently linked 
dimers can be formed by disulfide cross-linking and by electronic microscopy it seems as 
rod-like particles (Friedhoff et al., 2000). The dimers of Tau molecules become subunits of 
filaments, forming protomers, adopting the parallel, in register cross-ǃ-sheet structure 
typical of amyloid aggregates. On the basis of morphology and mass-per-unit length 
measurements, mature Tau filaments (PHFs) consist of two protofilaments wound around 
each other (Congdon et al., 2008). This has led to several proposed ‘‘nucleation-elongation’’ 
models of Tau fibril assembly (figure 5). In the classic equilibrium nucleation-elongation 
model elaborated for linear polymer formation, assembly-competent monomer is in rapid 
equilibrium with a thermodynamically unstable species termed the nucleus, in Tau case, 
probably the PHF-core (figure 4D). Once assembly-competent conformations are adopted 
(Weaver et al., 2000), the rate-limiting step in the reaction becomes dimerization, with 
subsequent aggregate growth occurring through monomer addition. When the critical 
nucleus cluster size is reached, subsequent additions to the nascent filament end are 
energetically favorable, and elongation proceeds efficiently (figure 5). This pathway leads to 
peaked distributions of filament lengths early in the reaction time series followed by slow 
relaxation toward exponential distributions at equilibrium. Finally, aggregation rates can be 
limited by secondary nucleation events, which occur on existing aggregates (Congdon et al., 
2008). In addition, an alternative linear colloidal aggregation model has been proposed for 
Tau in which the protein forms colloidal spheres that serve as nucleation units that, through 
charge-dipole and dipole-dipole interactions, go on to form linear fibers (Xu et al., 2010). 
Either pathway seems that adoption of assembly competent conformations, perhaps 
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associated with enriched ǃ-sheet content, can be driven by small diffusible ligands in a 
process that approximates homogeneous nucleation (Congdon et al., 2008). 
Pathologic Tau fibrils show diverse morphologies in diseased brains, where transmission 
electron microscopy (TEM) images typically reveal PHFs in AD NFTs or neuropil threads, 
although straight filaments (SFs) and twisted ribbons (TRs) are also seen (Xu et al., 2010). 
Those protofibrils seem to be wound around one another exposing a crossover repeat of~80 
nm, a maximal width of ~22 nm, and a narrow waist of ~12 nm. The twisted appearance is 
variable as follows: ~10% of Tau fibrils are straight filaments (Wegmann et al., 2010). 
Additional morphologic variants of Tau fibrils have been observed in other Tauopathies   
.  
Fig. 4. Characteristics of PHF-core. (A) Structure diagram and amino acid sequence of PHF 
core (Tau441). Although Tau presents a secondary random coil structure, the R2 and R3 of 
MTBD showed a motif with regional trend to ǃ-sheet structure. (B) Amino acid distribution 
histogram of PHF core; they are partially hydrophobic; (C) Proposed core structure based on 
predicted ǃ-strand propensities (Displayed in Jmol). (D) Electron Microscopy photograph of 
Tau aggregates induced by the presence of the PHF core. 
such as progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), Pick’s 
disease, and FTDP-17 syndromes. It seems that in these pathologies the crossover repeat is 
~160 nm. Likewise, Tau fibrils reassembled in vitro can display a variable twist between 
filaments assembled from different variants of Tau proteins (e.g. different  splicing variants) 
or even within a given filament (Wegmann et al., 2010). In the cellular environment protein 
expression, protein folding, and protein degradation are highly regulated processes. Protein 
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over-expression can lead to protein aggregation, which also is a regulated process. The 
molecular machines, from the microtubular transport system which assists protein folding 
and prevents aggregation, to the ubiquitin proteasome system and autophagic vacuoles, 
which degrade normal and aggregated proteins all work in concert. In a healthy cell they 
can maintain the equilibrium between synthesis, folding, function and degradation 
(Zerovnik, 2010). Recent evidence suggests that proteins that are able to constrain the 
structural freedom of Tau are essential for Tau processing and participate in its 
accumulation. Interactions of Tau with a specific family of proteins termed cis-trans 
peptidyl-prolyl isomerases (PPIases) has already revealed the importance of this protein 
family to regulate Tau phosphorylation cycles and its overall stability (Koren et al., 2011). 
Pin-1 is demostrated to interact with Tau through Thr231-P, promoting a conformational 
change that allows the action of phospatase PP2A over Tau (Bulbarelli et al., 2009). Recent 
findings suggest that FKBP51 has a similar activity to Pin1; however, unlike Pin1, FKBP51 
coordinates with Hsp90 to isomerize Tau. It also cooperates with distinct protein 
phosphatases that may also be novel participants in Tau biology. Recently is also suggested 
the participation of another isomerases like cyclophilin family, but is under research (Koren 
et al., 2011). In this matter chaperones, specially Hsp90, also can be necessary to maintain 
Tau in a non-aggregated state, a consequence that may ultimately be deleterious for the 
brain under pathological conditions (Koren et al., 2009).  
The phenomena are not stopped there. The accumulation and propagation of amyloidogenic 
proteins like Tau are believed to occur through nucleation-dependent polymerization and 
propagate in an extracellular manner. Tau may be released to the extracellular space upon 
neuron degeneration, where it could be toxic to other neurons (Ávila, 2010; Gómez-Ramos et 
al., 2006). This suggests that high molecular weight protein aggregates or amyloid seeds 
shed from one cell may easily be propagated to others (e.g. neurons or glial cells) under 
pathological conditions (e.g. alteration in membrane permeability due to aging or virus 
infection, impairment of membrane function as a result of physical interaction or abnormal 
membrane depolarization) that favor intracellular deposition of protein fibrils (Nonaka et 
al., 2010). Further investigation about this must be done. Until now, there is still an 
incomplete understanding of the sequence of events leading to Tau fibrillization, and it is 
unclear how the different structural variants of Tau fibrils arise or if these variants (PHFs, 
SFs, TRs) are interconvertible (Xu et al., 2010). And as a recent issue, the importance of 
extracellular misfolded Tau during aggregation issues and cellular components such as 
plasma membrane or mislocalization (Campos-Peña et al., 2009; Lira-De León, 2009), need 
more investigations. With this last purpose, in cell-models we noticed the enrichment of ǃ-
sheet structures in cells expressing PHF-core with a signal promoting the localization of it 
into Plasma membrane associated to presence of 441-Tau (Campos-Peña et al., 2009). Further 
investigation in this aim needs complementary studies. 
4. Conclusion  
Structural studies of amyloidogenic fibrils are crucial. The insolubility and stability of fibrils 
makes difficult to work with by conventional methods. The research has concentrated on the 
use of peptides for structural studies, but the information obtained is complex for the different 
conditions used in the assembly of amyloidogenic fibrils in Tau or AB proteins. There is a 
minimum sequence with amino acids partially hidrofobic that trend to form a ǃ-sheet 
structure, this region nucleating amyloidogenic fibril formation and is extremely insoluble. 
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Analysis of the amyloidogenic regions showed a high occurrence of the aromatic residues 
phenylalanine and tyrosine, which have a high propensity to stack the delocalized π-electron 
rings. Studies with short peptides have confirmed that even two consecutive phenylalanine 
residues are sufficient to facilitate assembly into nanotube-like structures. Protofibrils have 
been identified which appear to be fibrillar precursors to amyloidogenic fibril formation, and 
these are preceded by the appearance of small oligomers of Tau and AB. Whether these small 
intermediates interact directly to form protofibrils and then these elongate to form the fully 
formed fibril (figure 5). This process can be favored by interaction with membranes rich in 
negative charged surface, whereas the hydrophobic interior strengthens electrostatic 
secondary interactions and favors monomer recruitment with increase of local concentration, 
resulting in aggregate nucleation and membrane disassembly. Developing techniques for 
directly visualizing amyloidogenic fibrils at high resolution is promising solution to answer 
many key questions remain to be addressed. Elucidating these questions will undoubtedly 
reveal novel insights into diseases pathogenesis.  
 
Fig. 5. Common fibrillization pathway of amyloid-ǃ and Tau protein. Under physiological 
conditions, both proteins adopt a basal conformation (1), but when this is altered, they can 
adopt a pro-aggregatory conformation (enriched in ǃ-sheet structures). This abnormal 
conformation (2) allows the formation of dimers and the beginning of a nucleation phase (3). 
Continuous recruitment of pro-aggregatory forms lead to an elongation phase (4); which 
finally ends in the formations of fibrills or pores (5). 
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